| For Practicing Oncologists |
  See all
|
Article Summary
|
|
|
Gharibo M et al. - Single-agent imatinib does not have a significant activity in pancreatic cancer. Methods- Aim was to assess the clinical efficacy and toxicity of single-agent imatinib mesylate in pts with advanced, unresectable metastatic pancreatic cancer
- Previously treated/untreated pts with pancreatic adenocarcinoma with adequate organ and bone marrow function were enrolled
- Pts received imatinib 400 mg orally x2/d for a 28-day cycle
- Response was evaluated every 4 wks by imaging scans
- Response was defined as lack of tumor progression at 3 mos
Results- 11 pts were enrolled, and 9 were evaluable for response
- Best response was stable disease in 3 pts after 2 cycles of therapy
- All of them subsequently progressed
- No pts remained on treatment for 3 mos or longer, which was the response end point
- Median time to tumor progression was 47 days and median OS was 118 days
- The first 3 pts received imatinib 400 mg orally x2/d
- Due to unexpected grades 2 and 3 toxicities, the dose was reduced to 600 mg daily which was well tolerated
- Most common adverse events included grades 1 to 2 edema, liver enzyme elevations, nausea, and rash
--- HEPATOBILIARY/PANCREAS TOP ARTICLES ---
Receive free subspecialty "5-minute updates" via email
 |
| Sponsor |
--- PHARMACOLOGY/THERAPY TOP ARTICLES ---
Receive free subspecialty "5-minute updates" via email
|
 |
 |
| Sponsor |
|
|
| Read a Different Specialty |
 |
|
|
|
|
| Profession Index |
|
|
|
|
|
|
 |
| Sponsor |
 |
| Sponsor |
|
